0000904454-18-000650.txt : 20181004
0000904454-18-000650.hdr.sgml : 20181004
20181004211050
ACCESSION NUMBER: 0000904454-18-000650
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20181002
FILED AS OF DATE: 20181004
DATE AS OF CHANGE: 20181004
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Haskel William M.
CENTRAL INDEX KEY: 0001524372
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-36066
FILM NUMBER: 181109079
MAIL ADDRESS:
STREET 1: ONE MEADOWLANDS PLAZA
CITY: EAST RUTHERFORD
STATE: NJ
ZIP: 07073
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Paratek Pharmaceuticals, Inc.
CENTRAL INDEX KEY: 0001178711
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 330960223
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
BUSINESS PHONE: (617) 807-6600
MAIL ADDRESS:
STREET 1: 75 PARK PLAZA
STREET 2: 4TH FLOOR
CITY: BOSTON
STATE: MA
ZIP: 02116
FORMER COMPANY:
FORMER CONFORMED NAME: Transcept Pharmaceuticals Inc
DATE OF NAME CHANGE: 20090130
FORMER COMPANY:
FORMER CONFORMED NAME: NOVACEA INC
DATE OF NAME CHANGE: 20020724
4
1
edgar.xml
PRIMARY DOCUMENT
X0306
4
2018-10-02
0001178711
Paratek Pharmaceuticals, Inc.
PRTK
0001524372
Haskel William M.
C/O PARATEK PHARMACEUTICALS, INC.
75 PARK PLAZA, 4TH FLOOR
BOSTON
MA
02116
0
1
0
0
Sr. VP, Sec. & General Counsel
Common Stock
2018-10-02
4
A
0
17500
0
A
79774
D
Common Stock
2018-10-02
4
A
0
25000
0
A
104774
D
Common Stock
2018-10-03
4
S
0
5860
9.82
D
98914
D
Represents performance-based restricted stock units ("PRSUs") granted on February 2, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018.
Represents PRSUs granted on August 3, 2017 to the Reporting Person under the Paratek Pharmaceuticals, Inc. 2015 Equity Incentive Plan that vested on October 2, 2018. These PRSUs will settle in shares of common stock on October 2, 2019, provided that the Reporting Person remains in continuous service with Paratek Pharmaceuticals, Inc. through the settlement date.
Sale of shares to cover personal income tax obligations upon vesting of PRSUs, pursuant to Rule 10b5-1 trading plan.
The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions ranging from $9.75 to $9.95. The Reporting Person undertakes to provide to Paratek Pharmaceuticals, Inc., any security holder of Paratek Pharmaceuticals, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote 4 to this Form 4.
/s/ William M. Haskel
2018-10-04